Clinical trials: Lymphoma, Low-Grade
Multiple Myeloma, CLL / SLL
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.
- Conditions
- Multiple Myeloma, CLL / SLL, Non Hodgkin's Lymphoma, Waldenstroms
- Trial name
- NCT00714259
- Testing
- Fludarabine, Total Body Irradiation, Infusion of Stem Cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma.
- Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00253630
- Testing
- Laboratory Biomarker Analysis, Vorinostat
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00022685
- Testing
- epratuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Follicular Lymphoma
A Phase II Trial of Intermediate Radiation Dose For Lymphoma
The purpose of this study is to determine the optimal radiation dose fractionation regimen for low grade follicular lymphoma. It is hypothesized that the complete response rate with the use of 12 Gy in 6 daily fractions is 80%…
- Trial name
- NCT05284825
- Testing
- 12 Gy in 6 daily fractions
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
NHL, Lymphoma, Non-Hodgkin
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when…
- Conditions
- NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Follicular
- Trial name
- NCT00546793
- Testing
- veltuzumab
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.
- Trial name
- NCT00426855
- Testing
- Bendamustine, Bortezomib
- Volunteers
- 12 people
- Sponsor
- Peter Moosmann
Acute Myeloid Leukemia, Myelodysplasia
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in older adults or younger infirm patients with high-risk hematopoeitic malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00513318
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Non-Hodgkin's Lymphoma
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
The purpose of this study is to determine the optimal dose of subcutaneous CAMPATH when used in combination with rituximab for patients with relapsing or refractory, low-grade or follicular, CD-20-positive, B-Cell non-Hodgkin's…
- Trial name
- NCT00077961
- Testing
- CAMPATH (alemtuzumab)
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genzyme, a Sanofi Company
Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori
- Trial name
- NCT01264822
- Testing
- Rabeprazole Sodium
- Where
- 42 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Eisai Co., Ltd.
Brain and Central Nervous System Tumors, Lymphoma
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
RATIONALE: Finishing an antibiotic regimen at home may be as effective as receiving it in the hospital. It is not yet known whether early hospital discharge is as effective as standard inpatient care in cancer patients receiving…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neutropenia, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00445497
- Testing
- amoxicillin-clavulanate potassium, ciprofloxacin, psychosocial assessment and care
- Where
- 10 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Clatterbridge Centre for Oncology
Lymphoma
Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002510
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Temple University
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma.
- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma
- Trial name
- NCT06442475
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults.
- Trial name
- NCT01682746
- Testing
- Photofrin (porfimer sodium) & photodynamic therapy.
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Harry T Whelan, MD
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
The study addresses the question if a therapy with bendamustine plus rituximab is comparable (non inferior) with the well-tried combination of fludarabine plus rituximab with regard to event free survival (EFS) in recurrent low…
- Trial name
- NCT01456351
- Testing
- Bendamustine plus Rituximab, Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- University of Giessen
Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Low-Grade
- Trial name
- NCT00060671
- Testing
- rituximab, Pixantrone (BBR 2778)
- Where
- 38 sites in United States
- Volunteers
- 800 people
- Sponsor
- CTI BioPharma
B Cell Lymphoma, T Cell Lymphoma
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
The primary objective of this study is to evaluate the safety of intratumoral Polyinosinicpolycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC)(Hiltonol®) in addition to low-dose local radiotherapy…
- Trial name
- NCT00880867
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nevada Cancer Institute
Leukemia, Lymphoma
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00006252
- Testing
- fludarabine phosphate, Cyclophosphamide, PBSC
- Where
- 19 sites in United States
- Volunteers
- 47 people
- Sponsor
- Cancer and Leukemia Group B
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL
Patients on this study have a type of lymph gland cancer called non-Hodgkin Lymphoma or chronic Lymphocytic Leukemia. Their lymphoma or CLL has come back or has not gone away after treatment.
- Trial name
- ATECRAB (NCT00709033)
- Testing
- autologous or syngeneic PBTLs and EBV-CTLs
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline